Brandy Stepney, APRN
Family · Torrington, CTNPI 1598065245
Payments from drug & device makers
Across 631 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$879
- Johnson & Johnson$682
- Neurocrine Biosciences, Inc.$485
- Corium, LLC$440
- plus $3K from 29 others
What the payments were for
- Food & beverage$9,36097%
- Education$2653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 282 | $3,081 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 86 | $1,221 |
| Alkermes, Inc. | 33 | $879 |
| Johnson & Johnson | 39 | $682 |
| Neurocrine Biosciences, Inc. | 21 | $485 |
| Corium, LLC | 28 | $440 |
| Gilead | 18 | $434 |
| Otsuka America Pharmaceutical, Inc. | 22 | $367 |
| Novo Nordisk | 16 | $301 |
| AstraZeneca | 15 | $286 |
| Teva Pharmaceuticals USA, Inc. | 10 | $199 |
| Indivior Inc. | 6 | $131 |
| Lundbeck LLC | 6 | $128 |
| USWM, LLC | 7 | $118 |
| Axsome Therapeutics, Inc. | 5 | $104 |
| Viiv Healthcare Company | 4 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $89 |
| Lilly USA, LLC | 5 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $62 |
| Braeburn Inc. | 3 | $54 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Amgen | 1 | $34 |
| Bayer | 1 | $23 |
| Ardelyx, Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Orexo US, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Pfizer | 1 | $14 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,625 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 376 | $435,804 |
| Austedo XrDeutetrabenazine | 20 | $131,298 |
| VraylarCariprazine Hcl | 49 | $72,080 |
| OzempicSemaglutide | 44 | $58,352 |
| SunosiSolriamfetol Hcl | 38 | $45,160 |
| CaplytaLumateperone Tosylate | 27 | $43,623 |
| VivitrolNaltrexone Microspheres | 24 | $39,476 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 31 | $32,981 |
| RybelsusSemaglutide | 21 | $28,654 |
| Nurtec OdtRimegepant Sulfate | 18 | $25,955 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $25,138 |
| RexultiBrexpiprazole | 11 | $24,249 |
| Lurasidone Hcl | 21 | $22,579 |
| MounjaroTirzepatide | 16 | $16,680 |
| TrintellixVortioxetine Hydrobromide | 14 | $15,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $682 | $435,804376 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $199 | $131,29820 claims |
| Novo NordiskOzempic, Rybelsus | $301 | $87,00665 claims |
| AbbVieVraylar | $3,081 | $72,08049 claims |
| Axsome Therapeutics, Inc.Sunosi | $104 | $45,16038 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,221 | $43,62327 claims |
| PfizerNurtec Odt, Eliquis | $14 | $41,05934 claims |
| Alkermes, Inc.Vivitrol | $879 | $39,47624 claims |
| Orexo US, Inc.Zubsolv | $18 | $32,98131 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $367 | $24,24911 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $89 | $20,02626 claims |
| Lilly USA, LLCMounjaro | $85 | $16,68016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Torrington
- David OhotnickyTorrington$24K
- Lisa HautTorrington$13K
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.